Safety of Using Cultured Cells with Trisomy 7 in Cell Therapy for Treating Osteoarthritis

Overview

Journal Regen Ther

Date 2022 Jul 5

PMID 35785042

Authors

Mitsuru Mizuno

Nobutake Ozeki

Ichiro Sekiya

Affiliations

Soon will be listed here.

Abstract

Cell therapy is a promising alternative treatment approach currently under study for osteoarthritis (OA), the most common chronic musculoskeletal disease. However, the mesenchymal stem cells (MSCs) used in cell therapy to treat OA are usually expanded to obtain sufficient numbers for transplantation, and their safety has not been fully assessed from multiple perspectives. Analysis of karyotypic abnormalities, in particular, is important to ensure the safety of cells; however, chromosomal mutations may also occur during the cell-expansion process. In addition, there have been many reports showing chromosome abnormalities, mainly trisomy 7, in the cartilage and synovium of patients with OA as well as in normal tissues. The suitability of cells with these karyotypic abnormalities as cells for cell therapy has not been evaluated. Recently, we assessed the safety of using cells with trisomy 7 from the osteoarthritic joint of a patient for transplantation, and we followed up with the patient for 5 years. This study showed analysis for copy number variant and whole-genome sequencing, compared with blood DNA from the same patient. We did not find any abnormalities in the genes regardless of trisomy 7. No side effects were observed for at least 5 years in the human clinical study. This suggests that the transplantation of cultured cells with trisomy 7 isolated from an osteoarthritic joint and transplanted into the osteoarthritic joints of the same person is not expected to cause serious adverse events. However, it is unclear what problems may arise in the case of allogeneic transplantation. Different types of risks will also exist depending on other transplantation routes, such as localization to the knee-joint only or circulation inflow and lung entrapment. In addition, since the cause of trisomy 7 occurrence remains unclear, it is necessary to clarify the mechanism of trisomy 7 in OA to perform cell therapy for OA patients in a safe manner.

Citing Articles

iPSC-derived mesenchymal stem cells attenuate cerebral ischemia-reperfusion injury by inhibiting inflammatory signaling and oxidative stress.

Arakawa M, Sakamoto Y, Miyagawa Y, Nito C, Takahashi S, Nitahara-Kasahara Y Mol Ther Methods Clin Dev. 2023; 30:333-349.

PMID: 37637385 PMC: 10448333. DOI: 10.1016/j.omtm.2023.07.005.

Stress and motivation of cell processing operators: A pilot study of an online questionnaire survey.

Mizuno M, Sugahara Y, Iwayama D, Miyashita N, Katano H, Sekiya I Regen Ther. 2022; 21:547-552.

PMID: 36397824 PMC: 9643835. DOI: 10.1016/j.reth.2022.10.004.

References

Stumm M, Boger E, Gaissmaier C, Osswald C, Blankenburg M, Wegner R . Genomic chondrocyte culture profiling by array-CGH, interphase-FISH and RT-PCR. Osteoarthritis Cartilage. 2012; 20(9):1039-45. DOI: 10.1016/j.joca.2012.05.012. View

Bourne R, Chesworth B, Davis A, Mahomed N, Charron K . Patient satisfaction after total knee arthroplasty: who is satisfied and who is not?. Clin Orthop Relat Res. 2009; 468(1):57-63. PMC: 2795819. DOI: 10.1007/s11999-009-1119-9. View

Fletcher J, Henkle C, Atkins L, Rosenberg A, Morton C . Trisomy 5 and trisomy 7 are nonrandom aberrations in pigmented villonodular synovitis: confirmation of trisomy 7 in uncultured cells. Genes Chromosomes Cancer. 1992; 4(3):264-6. DOI: 10.1002/gcc.2870040312. View

Hayakawa T, Aoi T, Umezawa A, Ozawa K, Sato Y, Sawa Y . A study on ensuring the quality and safety of pharmaceuticals and medical devices derived from the processing of autologous human somatic stem cells. Regen Ther. 2019; 2:57-69. PMC: 6581870. DOI: 10.1016/j.reth.2015.05.002. View

Ermis A, Hopf T, Hanselmann R, Remberger K, Welter C, Dooley S . Clonal chromosome aberrations in cell cultures of synovial tissue from patients with rheumatoid arthritis. Genes Chromosomes Cancer. 1993; 6(4):232-4. DOI: 10.1002/gcc.2870060407. View

Sekiya I, Koga H, Otabe K, Nakagawa Y, Katano H, Ozeki N . Additional Use of Synovial Mesenchymal Stem Cell Transplantation Following Surgical Repair of a Complex Degenerative Tear of the Medial Meniscus of the Knee: A Case Report. Cell Transplant. 2019; 28(11):1445-1454. PMC: 6802148. DOI: 10.1177/0963689719863793. View

Elfving P, Cigudosa J, Lundgren R, Limon J, Mandahl N, Kristoffersson U . Trisomy 7, trisomy 10, and loss of the Y chromosome in short-term cultures of normal kidney tissue. Cytogenet Cell Genet. 1990; 53(2-3):123-5. DOI: 10.1159/000132910. View

Binato R, de Souza Fernandez T, Lazzarotto-Silva C, Du Rocher B, Mencalha A, Pizzatti L . Stability of human mesenchymal stem cells during in vitro culture: considerations for cell therapy. Cell Prolif. 2012; 46(1):10-22. PMC: 6496525. DOI: 10.1111/cpr.12002. View

Katano H, Ozeki N, Kohno Y, Nakagawa Y, Koga H, Watanabe T . Trends in arthroplasty in Japan by a complete survey, 2014-2017. J Orthop Sci. 2020; 26(5):812-822. DOI: 10.1016/j.jos.2020.07.022. View

10.

Singh J, Kundukulam J, Riddle D, Strand V, Tugwell P . Early postoperative mortality following joint arthroplasty: a systematic review. J Rheumatol. 2011; 38(7):1507-13. PMC: 4262531. DOI: 10.3899/jrheum.110280. View

11.

Mizuno M, Katano H, Mabuchi Y, Ogata Y, Ichinose S, Fujii S . Specific markers and properties of synovial mesenchymal stem cells in the surface, stromal, and perivascular regions. Stem Cell Res Ther. 2018; 9(1):123. PMC: 5930798. DOI: 10.1186/s13287-018-0870-9. View

12.

Ozeki N, Muneta T, Koga H, Nakagawa Y, Mizuno M, Tsuji K . Not single but periodic injections of synovial mesenchymal stem cells maintain viable cells in knees and inhibit osteoarthritis progression in rats. Osteoarthritis Cartilage. 2016; 24(6):1061-70. DOI: 10.1016/j.joca.2015.12.018. View

13.

Broberg K, Limon J, Palsson E, Lindstrand A, Toksvig-Larsen S, Mandahl N . Clonal chromosome aberrations are present in vivo in synovia and osteophytes from patients with osteoarthritis. Hum Genet. 1998; 101(3):295-8. DOI: 10.1007/s004390050631. View

14.

Salmon J, Rat A, Sellam J, Michel M, Eschard J, Guillemin F . Economic impact of lower-limb osteoarthritis worldwide: a systematic review of cost-of-illness studies. Osteoarthritis Cartilage. 2016; 24(9):1500-8. DOI: 10.1016/j.joca.2016.03.012. View

15.

Ferreira R, Irioda A, Cunha R, Francisco J, Guarita-Souza L, Srikanth G . Controversies about the chromosomal stability of cultivated mesenchymal stem cells: their clinical use is it safe?. Curr Stem Cell Res Ther. 2012; 7(5):356-63. DOI: 10.2174/157488812802481472. View

16.

Lee J, Pathak S, Hopwood V, Tomasovic B, Mullins T, Baker F . Involvement of chromosome 7 in primary lung tumor and nonmalignant normal lung tissue. Cancer Res. 1987; 47(23):6349-52. View

17.

Anderson J, Little D, Toth A, Moorman 3rd C, Tucker B, Ciccotti M . Stem cell therapies for knee cartilage repair: the current status of preclinical and clinical studies. Am J Sports Med. 2013; 42(9):2253-61. PMC: 4019709. DOI: 10.1177/0363546513508744. View

18.

Sekiya I, Katano H, Mizuno M, Koga H, Masumoto J, Tomita M . Alterations in cartilage quantification before and after injections of mesenchymal stem cells into osteoarthritic knees. Sci Rep. 2021; 11(1):13832. PMC: 8257723. DOI: 10.1038/s41598-021-93462-8. View

19.

Freitag J, Bates D, Boyd R, Shah K, Barnard A, Huguenin L . Mesenchymal stem cell therapy in the treatment of osteoarthritis: reparative pathways, safety and efficacy - a review. BMC Musculoskelet Disord. 2016; 17:230. PMC: 4880954. DOI: 10.1186/s12891-016-1085-9. View

20.

Pabinger C, Berghold A, Boehler N, Labek G . Revision rates after knee replacement. Cumulative results from worldwide clinical studies versus joint registers. Osteoarthritis Cartilage. 2012; 21(2):263-8. DOI: 10.1016/j.joca.2012.11.014. View